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selected. Two independent reviewers read the survival probabilities from KM
curves using an open source digitising software (Engauge digitizer). HRs for non-
overlapping time intervals were calculated from the estimated survival probabili-
ties and combined in a stratified way across time intervals to obtain an overall HR
using the spreadsheet by Tierney and colleagues. The estimated HR was compared
with the reported HR for each study. RESULTS: A mean error on the log scale of
0.001 (95%CI: 0.022, 0.019) was observed. This implies that by taking the expo-
nentials, if the reported HR is 0.750, then the estimated HR would be 0.749. The
95%CI for the mean error spans zero indicating any systematic error is likely to be
small and should not influence results in most analytic situations. Mean absolute
error on the log scale was 0.027 (95%CI: 0.016, 0.037) indicating calculated HR lie
within a factor of exponential (0.027) either side of the original value. No change in
the direction of the treatment effect was observed in the estimated HR (95%CI) for
any of the selected study. Reconstructed KM curves presented high accuracy and
reproducibility. CONCLUSIONS: KM curves could be potential source of data and it
is recommended that these should be used more frequently to estimate HR (95%
CI), where not reported explicitly, for conducting meta-analysis in systematic re-
views.
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OBJECTIVES: As more innovative oncology agents become available, budget limi-
tations are necessitating deeper value assessments of products. Previous research
demonstrated that examining a variety of key survival metrics is required to fully
define the value of an anti-neoplastic intervention. Here we examine how various
survival metrics compare across 3 major metastatic tumor types, chosen because
of the introduction of new therapeutics in the past year: melanoma, prostate and
lung cancer. METHODS: We conducted a literature-based review of pivotal clinical
trial data supporting new therapeutics in these tumor types from 2006-2012 and
selected all products with demonstrated overall survival benefit in the metastatic
setting: vemurafinib, ipilimumab for melanoma; cabazitaxel, abiraterone, sipuleu-
cel-T for prostate cancer; pemetrexed, erlotinib, and bevacizumab for lung cancer.
Crizotinib was excluded having not reached median overall survival (OS) at ap-
proval. We compared products on four survival metrics: median OS, mean OS,
1-year survival, and number needed to treat to avoid one event (NNT). RESULTS:
Despite variations in patient tumor types , the products showed a narrow range of
median OS improvement. However, greater variability was seen across other met-
rics: in lung cancer, pemetrexed presented the greater mean OS improvement,
while erlotinib demonstrated greater 1-year survival and lower NNT. In melanoma,
vemurafenib and ipilimumab demonstrated the same number of months of me-
dian OS improvement in their respective clinical trials; however, ipilimumab dem-
onstrated greater mean OS, 1-year survival, and lower NNT. In prostate cancer,
sipuleucel-T demonstrated better mean OS improvement, whereas abiraterone
had better 1-year survival and lower NNT. CONCLUSIONS: Drugs are being evalu-
ated with remarkably similar median OS benefits for metastatic patient popula-
tions. Side-by-side comparisons that take multiple endpoints into account can
assist decison makers to better understand total clinical benefit in context and
contribute to thoughtful resource management, especially when median OS ben-
efit may be so similar.
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OBJECTIVES: Due to pressure to provide rapid access despite uncertainty of a
drug’s real-world value, decision makers often require evidence from outcomes
research. We assessed whether a retrospective observational design can confirm
the trial-based efficacy for the novel agent bortezomib in advanced multiple my-
eloma and identify reasons for any discrepancies. METHODS: Two patient popu-
lations were included: real-world patients in the Netherlands (n72) and the bort-
ezomib pivotal trial population (n333). Data on real-world patients were
retrospectively collected from hospital records (period: 2001-2009). Baseline prog-
nostic factors, treatment patterns, safety and clinical outcomes were compared.
RESULTS: Overall response rates (49% versus 38%; p0.1) and time to progression
(median: 6.8 versus 6.2 months; p0.6) was similar compared to the trial though
the frequency of patient follow-up and definitions used for clinical outcomes var-
ied in daily practice. Overall survival was lower compared to the trial (median: 17.2
versus 29.8 months; p0.01) on account of differences in patient prognosis and use
of the drug. Daily practice patients were more heavily pre-treated in a shorter time
frame at baseline. Practice variation was observed in daily practice with the ma-
jority receiving bortezomib in combination with one or more drugs (68%). Conser-
vative administration was observed with lower cumulative dosages and fewer
treatment cycles (4 versus 6) in daily practice. Safety-related outcomes could not be
compared since this information in patient charts was frequently not detailed.
CONCLUSIONS: A retrospective design confirmed some but not all efficacy end-
points and identified reasons for discrepancies. Evidence generated from retro-
spective studies is complementary to that generated in a trial. Despite threats to
validity of the treatment effect, a retrospective design will generate valuable evi-
dence about who receives the drug and how it is given, which facilitates a feedback
loop to decision makers about ways to improve patient care and ultimately the
drug’s real-world value.
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OBJECTIVES: Immunosuppressive drugs have been subject to different evidence-
based assessments including evaluations along the regulatory process of the EMA
or reimbursement decisions by European HTA agencies. The objective of this re-
search was to review and compare the criteria applied for assessing immunosup-
pressive drugs in renal transplantation. Particular focus was set on the consisten-
cies and differences regarding assessment between the German IQWiG compared
to other European agencies. METHODS: A review of reports and guidelines on
subjects relevant for evidence-based assessment of immunosuppressive therapies
for renal transplantation which were published by EMA, IQWiG, and the European
HTA agencies of France, Scotland, Sweden and UK. The search was restricted to
documents in English or German. RESULTS: We identified relevant documents
from five agencies: one guidance document from EMA, HTA reports from the NICE
in UK, one advice from the SMC in Scotland, assessment summaries from the
French HAS and one report of early benefit assessment from the German IQWiG. No
relevant document was identified from the Swedish SBU. The EMA document pro-
vides guidance for planning of pivotal studies to evaluate safety and efficacy. The
HAS, NICE and SMC appraisals give advice for using immunosuppressive therapies
for renal transplantation and the IQWiG report assessed the additional benefit of
one new immunosuppressant. All documents recommended randomized con-
trolled trials (RCT) or systematic reviews of RCTs as the highest level of evidence.
Differences were in the clinical endpoints considered. In contrast to other agencies
the IQWiG did exclude the endpoints ‘graft function’ and ‘biopsy-confirmed acute
rejection’ from evaluation and did not consider compliance as relevant.
CONCLUSIONS: All agencies consistently recommend a similar standard for the
level of evidence. However, as long as there is no harmonization on the relevant
endpoints considered for evidence-based assessments, the different requirements
of local agencies should be considered when designing clinical trials and planning
statistical analyses.
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OBJECTIVES: According to the social law in Germany the Statutory Health Insur-
ance (GKV) has to address the three dimensions of disease: mortality, morbidity,
and quality of life. Consequently, the recently introduced EBA in Germany is group-
ing the benefits and the related endpoints into these dimensions. Our aim was to
examine the relative importance of each of those dimensions with regards to the
suggested benefit claims by the Institute for Quality and Efficiency in Health Care
(IQWiG). METHODS: The review includes EBAs that were started in 2011. The Joint
Federal Committee’s (GBA) webpage (http://www.g-ba.de/informationen/nutzen-
bewertung/) was used to obtain the respective IQWiG benefit assessments. The
benefit that IQWiG suggested was analysed for each assessment and the attribu-
tion of benefit to each of the three disease domains was examined. RESULTS:
Twenty-four EBAs were started in 2011. Two Orphan indications were excluded
from the analysis (Tafamidis Meglumin, Pirfenidon). In ten EBAs IQWiG suggested
a benefit for the related medication at least in one disease dimension and/or one
subgroup (Telaprevir, Abirateronacetat, Boceprevir, Ipilimumab, Belatacept,
Apixaban, Cabazitaxel, Fingolimod, Ticacrelor, Eribulin). In Abirateronacetat, Ipili-
mumab, Cabazitaxel, Ticacrelor, and Eribulin IQWiG suggested a mortality benefit.
With Ticacrelor IQWiG discriminated overall and cardiovascular mortality. In Tel-
aprevir, Abirateronacetat, Boceprevir, Apixaban, and Ticacrelor IQWiG suggested a
morbidity benefit. Due to the small number of eligible patients Fingolimod was
ultimately not examined regarding morbidity. No benefits were reported in the
dimension of Quality of Life. Side effects that were considered to cause additional
harm to patients and that negatively impacted the overall benefit rating were re-
ported in five EBAs: Boceprevir, Ipilimumab, Apixaban, Cabazitaxel, Eribulin.
CONCLUSIONS: In all reviewed assessments no benefit was attributed to Quality of
Life. The disease dimensions morbidity and mortality were of equal importance.
However, definitions of benefit within the dimension morbidity were very hetero-
geneous across the various EBAs
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OBJECTIVES: UK Pharma considers the UK a leading environment for the conduct
of Real World (RW) health care studies due to the influence of NICE, the cradle-to-
grave health care provided by the NHS, with GPs as the co-ordinators of care for
every patient and the widespread use of e-health records. Is there evidence for this
from research output? We reviewed abstracts published last year at ISPOR as one
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indicator of the influence of the UK in global RW research. METHODS: All 1455
abstracts presented at the ISPOR 14th Annual European Congress in Madrid, Spain
in 2011 were reviewed in THE ISPOR OUTCOMES RESEARCH DIGEST, available via
the ISPOR website. Posters were also reviewed where available. Those reporting RW
studies were classified according to: therapeutic area, type of study, setting, source
of data and methodology, country undertaken, country of authors and involve-
ment of commercial sponsors. RESULTS: A total of 278 abstracts (19%) described
RW studies. Data were derived from a database in 55.8%, health service/patient
medical records in 24.8%, surveys/questionnaires in 15.8% and other sources in
3.6%. 12% were conducted in the UK; a further 8% included UK centres in an inter-
national study. 24% were conducted in the USA, 53% in another country (not UK,
not USA – 38 countries, most commonly Spain 6%, Canada 5%, Germany 5%, France
5%, The Netherlands 3% and Italy 3%) and 3% were international without a UK
centre. In 21% of abstracts there was a UK author. CONCLUSIONS: RW studies
presented at the ISPOR European Congress 2011 were most often single country
rather than international with the USA being the most prolific source. Of the rest,
the UK was the source of RW data in twice as many studies as any other country,
lending weight to the opinion that the UK provides an excellent environment for
conducting RW studies.
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OBJECTIVES: It is widely recognized that regular exercise improves fitness, with
increasing evidence that physical activity (PA; movement resulting in elevated
energy expenditure beyond basal levels) can affect health, particularly in chronic
disease. While pharmacologic therapy and exercise training have been shown to
improve capacity, persistent increase in PA requires behavior change. This review
examined studies testing the effectiveness of behavioral interventions to increase
PA in adults with chronic disease. METHODS: Embase and PubMed searches of
intervention studies published in English, 1995-2011. Inclusion criteria: Adults 45
years; COPD, diabetes, heart failure, obesity; exercise or PA endpoint; behavioral
intervention described in sufficient detail to permit interpretation. RESULTS: A
total of 932 abstracts screened; 169 articles retrieved; 36 reviewed. Most were ran-
domized trials (n30, 83%) with 2 intervention arms (n29, 81%), medium to high
quality (n34, 94%). Subjects were recruited through clinical settings (n28, 78%),
with disease severity a primary eligibility criterion (n23, 64%); 15 (42%) had sam-
ple sizes 40-100. Mean study duration  9.6 months (range: 1-84). Exercise inter-
vention: 30-50 minutes aerobic activity 3-5 times/week (n22, 61%); 64% included
walking. Instruction was individual (n25, 69%), initially supervised (n24, 67%)
followed by unsupervised home exercise (n15, 42%). Behavioral intervention:
counseling (n19, 53%) with personal contact follow-up (n12, 33%). Control
group: exercise without behavioral intervention (n14, 39%) or usual care (n15,
42%). Significant effects of the intervention were reported in 15 of 25 (60%) studies
testing exercise capacity (6-minute walk, cycle or treadmill), 19 of 26 (73%) testing
PA outcomes (pedometer, activity log, questionnaire), 11 of 22 (50%) measuring
HRQL, and 8 of 13 (62%) capturing behavioral endpoints. CONCLUSIONS: This re-
view provides insight into the range of designs, interventions, and outcome mea-
sures used in studies testing methods to improve PA in chronic disease. Results
identify promising interventions, with implications for improving research meth-
ods and outcomes.
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OBJECTIVES: Guidelines for treatment of rheumatoid arthritis (RA) advise initial
therapy with non-biological disease modifying antirheumatic drugs (DMARDs). In
case patients do not respond adequately, treatment should be switched to biologic
DMARDs. Aim of this research is to compare results of public available systematic
reviews (SRs) on comparative effectiveness (CER) and potential impact of differ-
ences in methodology. METHODS: We performed literature research for SR on CER
of biologics for the treatment of RA. Search was limited to reviews published in
2009 or later. Methods of the reviews and results were extracted from the publica-
tions. Results are summarized in narrative way and differences in results are re-
flected focusing on methodological key issues. RESULTS: Eleven recent SRs were
identified addressing the question of CER of biologics. Since there are no head-to-
head comparisons available for all but one biologic, reviews had to use indirect
comparisons to assess CER. Authors used the Simon-Bucher approach or Bayesian
methods (mixed treatment comparisons). Clinical trial guidelines for RA give the
advice to use Response Criteria defined according to the American College of Rheu-
matology (ACR) as primary parameter. Therefore, all trials assessed ACR20 (20%
improvement), ACR50 and ACR70 and could be used for comparison. Further pa-
rameters were not assessed in a uniform manner (e.g. quality of life) or not as-
sessed in all trials (e.g. disease activity score) and therefore could not be used for
indirect comparison of treatments. CONCLUSIONS: Due to lack of head-to-head
data for comparison of biologics, statistical methods for indirect comparison have
to be used to answer the question of CER. These methods have restrictions and base
on assumptions that might be heavily violated. Substances were tested over a time
period of more than 10 years with effects on study population and variation in
study designs. Nevertheless, the results seem to be fairly consistent.
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OBJECTIVES:Clostridium difficileinfection (CDI) has been found to be associated with
increased inpatient length of stay (LoS), however the causal direction is unclear.
Many have attempted to correct for potential endogeneity bias by case matching
patients at the hospital level or by using instrumental variable regressions. We
propose an alternative method using propensity score matching on a nationwide
dataset to isolate the added effect of the disease using hospital level data.
METHODS: Using the Hospital Episode Statistics (HES) dataset for England, four
propensity scoring techniques were tested to estimate the causal effect of CDI on
LoS of patients over 50 years old, who have been diagnosed with diabetes, chronic
obstructive pulmonary disorder (COPD), heart failure, and/or chronic kidney dis-
ease. Methodological variations include radius matching, nearest neighbour
matching with and without replacement, and kernel matching. RESULTS: Control-
ling for a number of covariates, nearest neighbour matching with replacement
produces the least biased and most consistent estimates at 15.22 days longer LoS
after contracting CDI, with a post-matching pseudo-R2value of zero and a mean
absolute standardized bias of 0.51% compared to 41.53% before matching. Radius
matching produces less consistent results at 17.05 days, with a mean standardized
bias of 2.93% after matching. Kernel matching does not adequately account for bias
likely due to the largely unbalanced nature of the treatment versus control group.
CONCLUSIONS: Propensity score matching serves as an alternative method to tra-
ditional regression approaches to estimate the causal effect of CDI on patient LoS.
The results are consistent with those previously derived in the literature and dem-
onstrate the heavy burden of CDI on the English National Health Service.
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OBJECTIVES: Veterans Administration Corporate Data Warehouse stores data-
bases with standardized structure that could be used for automated data extrac-
tion, reviewer abstraction, and text mining to determine the association between
health outcomes and disease-specific factors. This retrospective study provides
assessment of VA administrative data used to examine the impact of pharmaco-
logical therapy on complications in ulcerative colitis (UC). METHODS: Previous
studies investigating the effect of 5ASA on the risk for colorectal cancer (CRC) in UC
patients have reported conflicting results. We obtained nationwide UC and CRC
data from VA health care system for the period 2001-2011. Secondary relational
databases were searched for clinical variables based on standardized criteria - ICD9
diagnoses, procedural and medication codes. Data extraction captured demo-
graphics, clinical information and pharmacy record for a cohort of 37,191 UC cases.
We constructed a dataset of potential ulcerative colitis cases with CRC (n1,087)
defined by ICD9 codes 556.x for UC, and 153.x,154.x and 159.0 for CRC. A random
subsample of 100 non-5ASA users with CRC was compared to 100 controls without
CRC. RESULTS: Diagnosis of ICD9 code for CRC had PPV 79% and NPV 100% in the
random sample. Within the 1087 potential CRC cases, only 500 (46%) were found to
have evidence of both conditions on chart review with kappa agreement between
automated and manual abstraction 0.73 (95% CI: 0.70-0.76) for CRC and significantly
lower for UC - 0.60 (95% CI: 0.57-0.63). The initial overall prevalence of CRC in the UC
cohort was 2.9% and decreased to 1.34% after human text search verification.
CONCLUSIONS: Automated extracts have great potential for diseases surveillance
but manual review yields more reliable data. Pre-defined diagnostic algorithms
based on a combination of methods as well as further technology development like
natural language processing and longitudinal patient record will improve accuracy
of retrospective databases.
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OBJECTIVES: Real-world data is considered to be the gold standard by decision
makers to inform on cost-effectiveness of new drugs. Unfortunately real-world
data are often lacking in important parameters needed to inform on cost-effective-
ness, and RCT data can be used to address this problem. Illustrated by two cases
this abstract will show that the manner in which RCT and real-world data are
combined can have a profound influence on the resulting ICER. METHODS: Two
case studies in which real-world data on cetuximab for the indication of locally
advanced head and neck cancer and panitumumab for the indication of chemo-
refractory metastatic colorectal cancer was collected retrospectively served as
examples. RESULTS: The problem: In the case of cetuximab, patient selection in
daily practice resulted in too much disparity in baseline characteristics between
the treated and control group. The solution: survival data for both treatment
groups from the pivotal RCT was used and corrected according to the results seen
in the real-world data to better represent survival in daily practice. Using unad-
justed RCT data resulted in a difference of approximately 5,000 euro/QALY in the
A461V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
